Oncoinvent ASA
ONCIN
Rang in aandelen
#27150
Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to... Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.
Aandeelprijs
$7.15
Marktkapitalisatie
$32.01M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
6,383.25%
Land
NO
Handel Oncoinvent ASA (ONCIN)
Categorie
Healthcare
Koersgeschiedenis voor Oncoinvent ASA (ONCIN)
Hoogste slotkoers: $9.10 op 2026-09-01
Laagste slotkoers: $27.86 op 2017-12-01
Laagste slotkoers: $27.86 op 2017-12-01
Koersgeschiedenis van Oncoinvent ASA van 2017 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 268.35% |
| 2025 | 32.73% |
| 2024 | -64.40% |
| 2023 | -90.91% |
| 2022 | 4.70% |
| 2021 | -41.35% |
| 2020 | 114.55% |
| 2019 | -57.70% |
| 2018 | 64.64% |
| 2017 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $534.12 | 25.25% |
US
|
|
| $231.12 | 760.78% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $880.75 | 8.18% |
NL
|
|
| $289.51 | 1.72% |
BE
|
